NEW YORK (GenomeWeb) – Lucence Diagnostics and Singapore's Quest Laboratories have announced a new partnership under which Quest will offer blood tests developed by Lucence for cancer detection and treatment guidance to its customers in the region.

The blood tests will be based on Lucence's proprietary liquid biopsy technology. The company says it has developed assays for cancers common in Asia, like lung and colon cancer. The same tests can also read out germline cancer predisposition mutations like BRCA1 and BRCA2.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
26
Sponsored by
PerkinElmer

This webinar will address the current status and future directions for massively high-throughput genomics for plant and animal breeding and research.